Facilitators of Peer Support Among Patients With Chronic Kidney Disease: A Systematic Review and Qualitative Meta-Synthesis.

J Ren CareOct 2, 2026
Clinical ResearchNephrology

Amir Faravan, Mansour Ghafourifard, Akram Ghahramanian et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and qualitative meta-synthesis examined facilitators of peer support among patients with chronic kidney disease (CKD). Analyzing 15 studies, it identified three key themes: supportive healthcare culture, strong peer connections, and engaged participants. The findings highlight the importance of these factors for effective peer support programs in CKD management.

Key findings

  • Three main themes were identified: supportive culture, deep connections, and engaged participants.
  • Successful peer support implementation relies on organizational support and meaningful relationships.
  • Active engagement of both peer supporters and recipients is crucial for program effectiveness.

Why it matters

Understanding the facilitators of peer support can enhance the design and integration of these programs in CKD care, potentially leading to improved clinical and psychosocial outcomes for patients.

Source

PubMed · PMID 42820648

Published in J Ren Care. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.